Immune Design Corp (NASDAQ:IMDZ) reported net loss for the first quarter of $ 12.62 million or $ 0.50 per share, compared to loss $ 12.29 million or $ 0.61 per share for the year-ago quarter.
The Seattle, Washington based company recorded Total Revenue for first quarter rose to $ 5.47 million from $ 1.86 million in the same quarter last year.
Analysts polled by Thomson Reuters expected IMDZ to report loss of $ 0.63 per share on revenue of $ 1.88 million for the first quarter.
The first quarter revenue was primarily attributable to $5.2 million in collaboration revenue associated with the Sanofi G103 (HSV2 therapeutic vaccine) collaboration and $0.3 million in product sales to other third parties.
Research and development expenses for the first quarter of 2017 were $14.0 million compared to $10.6 million for the same period in 2016.
Carlos Paya, President and CEO, said: During the first quarter of the year, we were pleased to complete enrollment in the first randomized studies for each of CMB305 and G100, an important milestone for Immune Design.